Guía de Práctica Clínica sobre Cuidados Paliativos - Cedepap TV

227. Clarkson J, Worthington H, Eden O. Interventions for preventing oral candidiasis for patientswith cancer receiving treatment. Cochrane Database of Systematic Reviews. 2007;2.228. Worthington H, Clarkson J, Eden O. Interventions for treating oral candidiasis for patientswith cancer receiving treatment. Cochrane Database of Systematic Reviews. 2007;2.229. Regnard C. Dysphagia, dyspepsia, and hiccup. In: Doyle D, Hanks G, Chreney N, Calman K,editors. Oxford Textbook of Palliative Medicine. Third ed. Oxford: Oxford University Press;2004. p. 459-68.230. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagiain esophageal cancer: a literature-based review. J Support Oncol. 2006;4(8):365-73, 379.231. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. ClinicalEvidence. London: BMJ Publishing Group; 2007. p. 1-12.232. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacyof antiemetics in the treatment of nausea in patients with far-advanced cancer2. Support Care Cancer. 2004;12(6):432-40.233. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. AmericanSociety of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J ClinOncol. 2006;24(18):2932-47.234. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapyinducednausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol.2000;18(19):3409-22.235. Jantunen IT, Kataja VV, Muhonen TT. An overview of randomised studies comparing 5-HT3receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapyinducedvomiting. Eur J Cancer. 1997;33(1):66-74.236. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A, et al. Additionof the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improvescontrol of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind,placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-8.237. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoidsfor control of chemotherapy induced nausea and vomiting: quantitative systematic review.BMJ. 2001;323(7303):16-21.238. Tramer MR, Reynolds DJ, Stoner NS, Moore RA, McQuay HJ. Efficacy of 5-HT3 receptorantagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review.Eur J Cancer. 1998;34(12):1836-44.239. Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasonecombination for the prevention of nausea and vomiting: a prospective, randomised study toassess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.Support Care Cancer. 1997;5(6):500-3.240. Supportive Care & Symptom Control Regimens. Management of Chemotherapy-inducedNausea and Vomiting. Disponible en http://www cancercare on ca/pdfchemo/NVguidelinespdf [accedido en: septiembre 2007]241. Hoskin P. Radiotherapy in symptom management. In: Doyle D, Hanks G, Chreney N, CalmanK, editors. Oxford Textbook of Palliative Medicine. Third ed. Oxford: Oxford UniversityPress; 2004. p. 239-59.300 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS